Drug Profile
Aurintricarboxylic acid-high molecular weight
Latest Information Update: 30 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antithrombotics
- Mechanism of Action GPIb receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Coronary artery restenosis; Thrombosis
Most Recent Events
- 26 Sep 1997 New profile
- 26 Sep 1997 Preclinical development for Atherosclerosis in USA (Unknown route)
- 26 Sep 1997 Preclinical development for Coronary artery restenosis in Japan (Unknown route)